Edu4U: The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes

Sponsor
University of Louisville (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02619487
Collaborator
(none)
0
1
4
9.4
0

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether a simple text message reminder sent to the parent of an child/adolescent with Type 1 Diabetes(or parent and adolescent) is effective in helping the individual(or parent) become more compliant with self-managing the Type 1 Diabetes (T1D). There will be 5 arms: text message sent to parents of children age 8-12 years old with T1D, text messages sent to parents of adolescents ,age 13-18 years old, with T1D,text messages sent to parents of adolescents with T1D as well as the adolescent with T1D,no text message sent to parents of children age 8-12 years, and no text message sent to adolescents or parents of adolescents age 13-18 years old.

Condition or Disease Intervention/Treatment Phase
  • Other: text message to parent only
  • Other: text message to parent and adolescent
N/A

Detailed Description

Managing Type 1 Diabetes requires daily checks of blood glucose and medication adjustments. Children and adolescents are known to have more difficulty with this than adults. Parents/legal guardians also face the task of helping with this self-management. A weekly text message regarding Type 1 Diabetes, sent to the parent or the parent and adolescent, may help to remind and motivate an individual to perform the daily tasks needed to manage their Type 1 Diabetes.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes
Anticipated Study Start Date :
Mar 1, 2019
Anticipated Primary Completion Date :
Dec 13, 2019
Anticipated Study Completion Date :
Dec 13, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: 8-12 years old, parent receiving text

text message to parent only

Other: text message to parent only
A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
Other Names:
  • e-health intervention
  • Active Comparator: 13-18 years old, parent receiving text

    text message to parent only

    Other: text message to parent only
    A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
    Other Names:
  • e-health intervention
  • Active Comparator: 13-18 years, both receiving text

    Text message to parent and adolescent

    Other: text message to parent and adolescent
    A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year

    No Intervention: No text

    No text will be sent

    Outcome Measures

    Primary Outcome Measures

    1. glycemic control assessed by HbA1C level. [up to one year after randomization occurs]

      review of lab value

    Secondary Outcome Measures

    1. number of episodes of Diabetic Ketoacidosis (DKA) [up to one year after randomization occurs]

      chart review of self reported episodes of Diabetic Ketoacidosis and chart review of hospitalizations related to DKA

    2. number of episodes of severe hypoglycemia [up to one year after randomization occurs]

      chart review of reported episodes of severe hypoglycemia and chart review of hospitalizations related to hypoglycemia

    3. number of patient contacts to the diabetes educator [up to one year after randomization occurs]

      chart review of educator documentation of communication with subject

    4. number of hospitalizations related to T1D [up to one year after randomization occurs]

      chart review of hospitalizations related to T1D

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    8 Years to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Be willing to agree to participate(assent) in the study and have the permission of the parent to do so.

    2. Have a diagnosis of Type 1 diabetes for ≥ one year.

    3. Be aged 8 to 18 years old.

    4. Be on insulin therapy for ≥ one year.

    5. Have a parent/legal guardian with access to a working cell phone or have a parent/legal guardian with access to a working cell phone and have a working cell phone (if 13 years of age or older).

    6. Utilize one of the following mobile carriers: T-Mobile, Sprint, Verizon, AT&T, or Virgin Mobile.

    7. The parent/legal guardian must express intent to maintain a carrier plan for the duration of the study.

    8. The parent/legal guardian must be able to read English OR the parent/legal guardian and the adolescent must be able to read English.

    Exclusion Criteria:
    1. Participants, who in the opinion of the investigator, have any contraindication to tight glycemic control.

    2. Individuals who are unable to undertake blood glucose testing during the study period

    3. Individuals who are deemed unable or unlikely to comply with the protocol.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Louisville Louisville Kentucky United States 40202

    Sponsors and Collaborators

    • University of Louisville

    Investigators

    • Principal Investigator: Gwendolyn S Pierce, MSN, University of Louisville

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Gwendolyn Pierce, Research Nurse, University of Louisville
    ClinicalTrials.gov Identifier:
    NCT02619487
    Other Study ID Numbers:
    • 01
    First Posted:
    Dec 2, 2015
    Last Update Posted:
    Dec 17, 2018
    Last Verified:
    Dec 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 17, 2018